Investor Sues Hemispherx As FDA Denies Fatigue Drug
The U.S. Food and Drug Administration will not approve Hemispherx Biopharma Inc.'s chronic fatigue syndrome drug Ampligen anytime soon, the company announced Tuesday, the same day a shareholder filed another putative...To view the full article, register now.
Already a subscriber? Click here to view full article